VivoSeq
Gastroenterology

Alcoholic Liver Cirrhosis

5

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Alcoholic Liver Cirrhosis is an early-stage landscape with 5 programs across 3 companies. The most active players are Rohto Pharmaceutical Co., Ltd., Novartis, Bayer. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Rohto Pharmaceutical Co., Ltd.

1 program

Phase 2Novartis logo

Novartis

1 program

ApprovedBayer logo

Bayer

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSCell therapy133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

3

clinical trials

Completed1 · 33%
Unknown status1 · 33%
Recruiting1 · 33%

Clinical Trials

Trial Activity

REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)
Completed·PPharmicell Co., Ltd.·Phase 2·NCT01875081·72 enrolled
The Effectiveness and Safety for Mesenchymal Stem Cell for Alcoholic Liver Cirrhosis
Unknown status·YYonsei University·Phase 2·NCT01741090·12 enrolled
Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study
Recruiting·PPharmicell Co., Ltd.·N/A·NCT05093881·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)